Author

A. Mottok

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Chang· 1 shared A. Dhogan· 1 shared A. Melnick· 1 shared A. Telenius· 1 shared A. Younes· 1 shared C. K. Rushton· 1 shared C. Steidl· 1 shared C. Yee· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chang

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Non-coding NFKBIZ 3' UTR mutations promote cell growth and resistance to targeted therapies in diffuse large B-cell lymphoma

S. E. Arthur, J. Gao, S. Healy, C. K. Rushton, N. Thomas, L. K. Hilton, K. Dreval, J. Tang, M. Alcaide, R. Cojocaru, A. Mottok, A. Telenius, P. Unrau, W. H. Wilson, L. M. Staudt, , R. D. Morin

This study identifies non-coding NFKBIZ 3' UTR mutations as drivers of DLBCL growth and resistance to NF-κB-targeted therapies, suggesting their potential as biomarkers.

bioRxiv · May 22, 2021 · PreprintCancer Biology

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

P. Mondello, S. Tadros, M. Teater, L. Fontan, A. Chang, N. Jain, S. Singh, M. C. J. Ma, H. Yang, E. Toska, S. Alig, M. Durant, E. de Stanchina, A. Mottok, L. Nastoupil, , M. Green

This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.

bioRxiv · Jan 27, 2019Cancer Biology